Aliases & Classifications for Mouth Disease

MalaCards integrated aliases for Mouth Disease:

Name: Mouth Disease 12 15 17
Mouth Diseases 44 72
Mouth Disorders 43


External Ids:

Disease Ontology 12 DOID:403
MeSH 44 D009059
NCIt 50 C27641 C3240
UMLS 72 C0026636

Summaries for Mouth Disease

MedlinePlus : 43 Your mouth is one of the most important parts of your body. It has many different functions. It allows you to Take in food and drink Breathe in air Start digestion, with your teeth chewing the food you eat and your salivary glands releasing saliva to help break down the food Speak and sing Show emotion, by smiling or pouting Any problem that affects your mouth can make it hard to eat, drink, or even smile. Some common mouth problems include Cold sores - painful sores on the lips and around the mouth, caused by a virus Canker sores - painful sores in the mouth, caused by bacteria or viruses Thrush - a yeast infection that causes white patches in your mouth Leukoplakia - white patches of excess cell growth on the cheeks, gums or tongue, common in smokers Dry mouth - a lack of enough saliva, caused by some medicines and certain diseases Gum or tooth problems Bad breath Treatment for mouth disorders varies, depending on the problem. If a mouth problem is caused by some other disease, treating that disease can help. It is also important to keep your mouth clean and healthy by brushing, flossing, and not using tobacco.

MalaCards based summary : Mouth Disease, also known as mouth diseases, is related to hand, foot and mouth disease and meningitis, and has symptoms including tinnitus, halitosis and snoring. An important gene associated with Mouth Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Mannitol and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include testes, kidney and t cells, and related phenotypes are hematopoietic system and cardiovascular system

Disease Ontology : 12 A gastrointestinal system disease that is located in the mouth.

Related Diseases for Mouth Disease

Diseases related to Mouth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 328)
# Related Disease Score Top Affiliating Genes
1 hand, foot and mouth disease 34.7 TLR3 SCARB2 IL6 IL17F IL10 IFNG
2 meningitis 31.3 IL6 IL10 IFNG CRP
3 brucellosis 31.2 TLR4 IL6 IL10 IFNG CRP
4 japanese encephalitis 31.1 TLR3 STAT1 DDX58
5 nervous system disease 31.0 IL6 IL10 IFNG CRP
6 coccidioidomycosis 31.0 TLR4 STAT1 IL10
7 trypanosomiasis 30.9 IL6 IL10 IFNG
8 endocarditis 30.9 IL6 IL10 CRP
9 viral infectious disease 30.9 TLR7 TLR3 STAT1 IL6 IL10 IFNG
10 measles 30.8 TLR3 STAT1 IL6 IFNG IFNA1 DDX58
11 perinatal necrotizing enterocolitis 30.7 TLR4 IL6 CRP
12 hematopoietic stem cell transplantation 30.7 IL6 IL10 IFNG
13 severe acute respiratory syndrome 30.7 STAT1 IFNG IFNA1 CRP
14 chlamydia 30.7 TLR4 IL6 IL10 IFNG CRP
15 pericarditis 30.7 IL6 IFNG CRP
16 acute pancreatitis 30.7 IL6 IL10 CRP
17 bone inflammation disease 30.6 IL6 IL10 IFNG CRP
18 appendicitis 30.6 IL6 IL10 HMGB1 CRP
19 peritonitis 30.6 IL6 IL10 CRP
20 graft-versus-host disease 30.6 IL6 IL10 IFNG
21 gastroenteritis 30.6 IL6 IL10 IFNA1 CRP
22 autoimmune disease 30.6 IL6 IL10 IFNG IFNA1
23 acquired immunodeficiency syndrome 30.5 IL6 IL10 IFNG IFNA1
24 kawasaki disease 30.5 IL6 IL10 CRP
25 bronchiolitis 30.5 TLR4 IL6 IL10 IFNG CRP
26 periodontitis 30.5 TLR4 IL6 IL10 IFNG CRP
27 human immunodeficiency virus type 1 30.4 TLR3 STAT1 IL6 IL10 IFNG IFNA1
28 acute transverse myelitis 30.4 IL6 IL10
29 influenza 30.3 TLR7 TLR3 IFNG IFNA1 DDX58
30 burning mouth syndrome 11.5
31 pyelitis 10.9 TLR4 IL6 CRP
32 central nervous system vasculitis 10.9 IL6 IFNG CRP
33 relapsing polychondritis 10.9 IL6 IFNG CRP
34 cold agglutinin disease 10.9 IL6 CRP
35 variola major 10.9 TLR4 TLR3 IFNG
36 cystic echinococcosis 10.9 TLR4 IL6 IL10
37 viral meningitis 10.9 IL6 IFNG CRP
38 intermediate uveitis 10.9 IL6 IL10 IFNG
39 eales disease 10.9 IL6 IL10 IFNG
40 acute pyelonephritis 10.9 IL6 IL10 CRP
41 scrub typhus 10.9 TLR4 IL10 CRP
42 cephalosporin allergy 10.8 IL10 IFNG
43 lymph node disease 10.8 IL6 IL10 CRP
44 bacterial sepsis 10.8 TLR4 IL10 CRP
45 plasmodium vivax malaria 10.8 IL6 IL10 IFNG
46 spondyloarthropathy 10.8 IL6 IL10 IFNG
47 bacterial pneumonia 10.8 TLR4 IL6 CRP
48 mixed connective tissue disease 10.8 IL6 IL10 IFNG
49 prostatitis 10.8 VDR IL6 IL10
50 temporal arteritis 10.8 IL6 IFNG CRP

Graphical network of the top 20 diseases related to Mouth Disease:

Diseases related to Mouth Disease

Symptoms & Phenotypes for Mouth Disease

UMLS symptoms related to Mouth Disease:

tinnitus, halitosis, snoring, sore throat, coughing, vertigo/dizziness, equilibration disorder, oral manifestations

MGI Mouse Phenotypes related to Mouth Disease:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.34 BECN1 DDX58 IFNG IL10 IL17F IL6
2 cardiovascular system MP:0005385 10.33 BECN1 CRP G3BP1 IFNG IL10 IL6
3 homeostasis/metabolism MP:0005376 10.32 BECN1 CRP DDX58 IFNG IL10 IL6
4 immune system MP:0005387 10.3 BECN1 CRP DDX58 IFNG IL10 IL17F
5 growth/size/body region MP:0005378 10.29 BECN1 DDX58 G3BP1 IFNG IL10 IL17F
6 cellular MP:0005384 10.28 BECN1 DDX58 G3BP1 IFNG IL10 IL6
7 mortality/aging MP:0010768 10.24 BECN1 DDX58 G3BP1 G3BP2 IFNG IL10
8 digestive/alimentary MP:0005381 10.18 DDX58 IFNG IL10 IL17F IL6 NOTCH1
9 integument MP:0010771 10.03 BECN1 IFNG IL10 IL6 NOTCH1 STAT1
10 liver/biliary system MP:0005370 9.95 DDX58 IFNG IL10 IL6 NOTCH1 STAT1
11 muscle MP:0005369 9.92 IFNG IL10 IL6 NOTCH1 STAT1 TLR3
12 neoplasm MP:0002006 9.91 BECN1 DDX58 IFNG IL10 IL6 NOTCH1
13 nervous system MP:0003631 9.9 BECN1 G3BP1 IFNG IL10 IL6 NOTCH1
14 renal/urinary system MP:0005367 9.5 IFNG IL6 NOTCH1 SCARB2 TLR4 TLR7
15 respiratory system MP:0005388 9.23 G3BP1 IFNG IL10 IL17F IL6 NOTCH1

Drugs & Therapeutics for Mouth Disease

Drugs for Mouth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
Ribavirin Approved Phase 4 36791-04-5 37542
3 Antiviral Agents Phase 4
4 Antimetabolites Phase 4
5 Antibodies, Blocking Phase 4
6 Antibodies Phase 4
7 Immunoglobulins Phase 4
8 Vaccines Phase 4
9 Immunologic Factors Phase 4
10 Anti-Infective Agents Phase 3
11 Anti-Infective Agents, Local Phase 3
12 Disinfectants Phase 3
13 Chlorhexidine gluconate Phase 3
14 Dermatologic Agents Phase 3
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 2 7487-88-9 24083
Nicotine Approved Phase 1, Phase 2 54-11-5 942 89594
Aluminum sulfate Approved Phase 2 10043-01-3
Ibuprofen Approved Phase 2 15687-27-1 3672
Acetaminophen Approved Phase 2 103-90-2 1983
Sucralfate Approved Phase 2 54182-58-0
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
Lobeline Investigational Phase 2 90-69-7
25 Adjuvants, Immunologic Phase 2
26 Hormones Phase 2
27 Autonomic Agents Phase 2
28 Central Nervous System Depressants Phase 2
29 Tocolytic Agents Phase 2
30 Retinol palmitate Phase 2
31 retinol Phase 2
32 Anesthetics Phase 2
33 Anti-Arrhythmia Agents Phase 2
34 Anticonvulsants Phase 2
35 calcium channel blockers Phase 2
36 Calcium, Dietary Phase 2
37 Neurotransmitter Agents Phase 2
38 Cholinergic Agents Phase 2
39 Central Nervous System Stimulants Phase 2
40 Nicotinic Agonists Phase 2
41 Respiratory System Agents Phase 2
42 Pharmaceutical Solutions Phase 2
43 Gastrointestinal Agents Phase 2
44 Antacids Phase 2
45 Anti-Ulcer Agents Phase 2
46 Anti-Inflammatory Agents Phase 2
47 Peripheral Nervous System Agents Phase 2
48 Cyclooxygenase Inhibitors Phase 2
49 Analgesics, Non-Narcotic Phase 2
50 Analgesics Phase 2

Interventional clinical trials:

(show top 50) (show all 94)
# Name Status NCT ID Phase Drugs
1 Effect and Safety of Xiao'er Jiebiao Oral Liquid in Combination With Standard Treatment on Hand-foot-mouth Disease in Pediatric Patients Completed NCT02328651 Phase 4 Ribavirin plus Xiao'er jiebiao oral liquid;Ribavirin
2 A Opened,Randomized and Controlled Trial to Evaluate the Immunity and Safety of Sequential Vaccination of Two Different Commercial EV71 Inactived Vaccines in Healthy Infants Aged 6-35 Months Completed NCT03873740 Phase 4
3 A Phase IV Open-labelled, Single-centered, Stratified-randomized Clinical Trial in Zhejiang Province to Evaluate the Safety and Immunogenicity of EV71 Vaccine Developed by Sinovac Biotech Co., Ltd. Completed NCT03278132 Phase 4
4 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Recombinant Hepatitis B Vaccine/Group A Meningococcal Polysaccharide Vaccine Completed NCT03274102 Phase 4
5 Effectiveness and Safety of Inactivated EV71 Vaccine (Human Diploid Cell) in 6-71 Months Children: an Open-label Controlled Phase Ⅳ Clinical Study Completed NCT03001986 Phase 4
6 Peri-implantitis - Regenerative Treatment With Enamel Matrix Derivative (EMD). Clinical Effects, Microbial Profiles and Molecular Mechanisms. A Randomised Controlled Pilot Study. Completed NCT02500654 Phase 4
7 Phase Ⅳ Clinical Trial, to Evaluate the Efficacy of the Enterovirus 71 (EV71) Inactivated Vaccine and Its Correlation With EV71 Antibody Level Recruiting NCT03903926 Phase 4
8 Study on Immunogenicity of Inactivated Enterovirus 71 (EV71) Vaccine (Human Diploid Cell, KMB-17) in Large-scale Healthy Children in China Active, not recruiting NCT03240744 Phase 4
9 The Safety, Immune Persistence and Consistency of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17) Active, not recruiting NCT02999828 Phase 4
10 A Phase IV Clinical Trial for Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71: A Multicenter, Case-control Study. Enrolling by invitation NCT03582761 Phase 4
11 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Enrolling by invitation NCT03296410 Phase 4
12 Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months Not yet recruiting NCT02889497 Phase 4
13 Three Batches Consistency, Immunity Duration and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China Not yet recruiting NCT03893747 Phase 4
14 A Multicentered, Double - Blind, Randomized, and Placebo - Controlled Clinical Trial With Inactivated Enterovirus Type 71 (EV71) Vaccines Completed NCT01507857 Phase 3
15 A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months Completed NCT01508247 Phase 3
16 Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine: A Double-blind, Randomized and Controlled Trial Completed NCT01636245 Phase 3
17 Multi-Center Phase 3 Trial of Chlorhexidine Gluconate Chip for the Use in Subjects With Peri-Implantitis. Completed NCT02080403 Phase 3 2.5 mg Chlorhexidine gluconate chip
18 A Phase III Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants and Children Completed NCT01569581 Phase 3
19 A Phase III Clinical Trial With Randomized, Double-blinded, Controlled Design as Well as Bridging Design to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Children Aged 36-71 Months Recruiting NCT03909074 Phase 3
20 An Open-Label, Dose-Finding, Phase II Study to Evaluate the Immunogenicity and Safety of the Bioreactor-generated EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 2 to 35 Months Old Unknown status NCT03268083 Phase 2
21 A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Chemotherapy and Radiotherapy Unknown status NCT01247246 Phase 2 SCV-07;Placebo
22 Periapical Bone Healing After Apicectomy With and Without Retrograde Root Filling Unknown status NCT00228280 Phase 1, Phase 2
23 A Phase II Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants Completed NCT01512706 Phase 2
24 A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Magnesium Sulfate for the Management of Severe Hand, Foot and Mouth Disease With Autonomic Nervous System Dysregulation in Vietnamese Children. Completed NCT01940250 Phase 2 Magnesium Sulphate;Sterile water
25 Phase II, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of the Effects of RK-0202 on Oral Mucositis in Patients Receiving Radiation Therapy for Tumors of the Oral Cavity, Oropharynx, Nasopharynx, Salivary Glands or Supraglottic Region Completed NCT00230191 Phase 2 RK-0202
26 A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of CG53135-05 Administered Intravenously as a Single Dose for the Prevention of Oral Mucositis in Patients Receiving Autologous Hematopoietic Stem Cell Transplant Completed NCT00104065 Phase 2 CG53135-05, velafermin
27 A Phase II Randomized Double Blind Placebo Controlled Trial to Assess Safety and Efficacy of Velafermin for Prevention of Oral Mucositis in Hematologic Cancer Patients Receiving Autologous Stem Cell Transplant Completed NCT00323518 Phase 2 velafermin;placebo
28 An Open-label, Dose-finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old Completed NCT02777411 Phase 2
29 A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01399853 Phase 2
30 Evaluation of the Clinical Effects of Tooth Powder on Plaque Induced Gingivitis Completed NCT01902095 Phase 2
31 A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Completed NCT01734408 Phase 2
32 Treatment of Smokeless Tobacco Users Completed NCT00218270 Phase 2 Tobacco free snuff
33 Treatment of Smokeless Tobacco Users: Use of Nicotine Replacement Products to Reduce Smokeless Tobacco Use Completed NCT00218244 Phase 1, Phase 2
34 An Adaptive Phase 2 Randomized Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Multiple LOU064 Doses in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe) Recruiting NCT04035668 Phase 2 LOU064;Placebo
35 A Randomized, Parallel-group Autogenous ex Vivo Produced Oral Mucosa Equivalent vs. Palatal Oral Mucosa Safety and Efficacy Study in Subjects Requiring Additional Keratinized Oral Mucosa for Dental Implants Active, not recruiting NCT01834326 Phase 1, Phase 2
36 Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial Enrolling by invitation NCT03241030 Phase 2 Sucralfate;Acetaminophen;Ibuprofen
37 Intraoral Grafting of Ex Vivo Produced Oral Mucosal Composites Unknown status NCT00000111 Phase 1
38 Phase I, Double Blind, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of a Prophylactic Vaccine Against Enterovirus Infection in Healthy Adults Completed NCT01376479 Phase 1
39 A Blind, Randomized and Placebo-controlled Clinical Trial With Inactivated Enterovirus Type 71 Vaccines in Healthy Children. Completed NCT01273246 Phase 1
40 A Phase Ia Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children Completed NCT01267903 Phase 1
41 A Phase Ib Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01313715 Phase 1
42 A Phase I Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Adults, Children and Infants Completed NCT01391494 Phase 1
43 Evaluation of Polarized Reflectance Spectroscopy for Detection of High-risk Oral Lesions Completed NCT01604759 Phase 1
44 A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium in Healthy Chinese Adults Recruiting NCT03804749 Phase 1 suramin sodium
45 Validation and Dosimetry Study of [18F]-FBA-A20FMDV2 PET Ligand for Alpha(V)beta6 in Healthy Subjects and in the Lungs of Idiopathic Pulmonary Fibrosis (IPF) Subjects (PETAL Study) Terminated NCT02052297 Phase 1
46 A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease Unknown status NCT01145664 Herbal concentrate-granules plus western therapy;Reduning Injection plus western therapy;Western therapy
47 A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Unknown status NCT01182025 Xiyanping Injection;Xiyanping Injection with western medicine
48 A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Unknown status NCT01175915
49 Burning Mouth Disorder (BMD) - a Neuropathic Pain Disorder? An Investigation Using Qualitative and Quantitative Sensory Testing (QST) Unknown status NCT00504387
50 Efficacy of Tobacco Cessation for Improving Oral Diseases - Multicenter Prospective Trial Unknown status NCT02737176

Search NIH Clinical Center for Mouth Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Lidocaine Hydrochloride

Cochrane evidence based reviews: mouth diseases

Genetic Tests for Mouth Disease

Anatomical Context for Mouth Disease

MalaCards organs/tissues related to Mouth Disease:

Testes, Kidney, T Cells, Tongue, Salivary Gland, Skin, B Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Mouth Disease:


Publications for Mouth Disease

Articles related to Mouth Disease:

(show top 50) (show all 9137)
# Title Authors PMID Year
Richard Watt: time to tackle oral diseases. 17
31327362 2019
Oral diseases: a global public health challenge. 17
31327369 2019
Ending the neglect of global oral health: time for radical action. 17
31327370 2019
Functionalized selenium nanoparticles enhance the anti-EV71 activity of oseltamivir in human astrocytoma cell model. 38
31422717 2019
Pathological and molecular studies on Coxsackie virus A-16 isolated from hand, foot, and mouth disease cases in India: Approach using neonatal mouse model. 38
31237683 2019
Probe capture enrichment next-generation sequencing of complete foot-and-mouth disease virus genomes in clinical samples. 38
31336142 2019
In Vitro and In Vivo Inhibition of the Infectivity of Human Enterovirus 71 by a Sulfonated Food Azo Dye, Brilliant Black BN. 38
31167919 2019
Comparative analysis of putative novel microRNA expression profiles induced by enterovirus 71 and coxsackievirus A16 infections in human umbilical vein endothelial cells using high-throughput sequencing. 38
31176031 2019
Immune cells transferred by colostrum do not influence the immune responses to foot-and-mouth disease primary vaccination. 38
31301846 2019
Inhibitory effects of homoharringtonine on foot and mouth disease virus in vitro. 38
31032977 2019
Comparison of Nonpolio Enteroviruses in Children With Herpangina and Hand, Foot and Mouth Disease in Taiwan. 38
31033911 2019
Epidemic growth rates and host movement patterns shape management performance for pathogen spillover at the wildlife-livestock interface. 38
31401952 2019
Diagnostic comparison of serum and EDTA-stabilized blood samples for the detection of foot-and-mouth disease virus RNA by RT-qPCR. 38
31095976 2019
Genome Sequences of 18 Foot-and-Mouth Disease Virus Outbreak Strains of Serotype O Sublineage Ind2001d from India, 2013 to 2014. 38
31416875 2019
Mitochondria Redistribution in Enterovirus A71 Infected Cells and Its Effect on Virus Replication. 38
31069716 2019
Enterovirus 71 VP1 promotes mouse Schwann cell autophagy via ER stress‑mediated PMP22 upregulation. 38
31173167 2019
Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPs) vaccine produced in Pichia pastoris. 38
31403352 2019
Enterovirus A71 neurologic complications and long-term sequelae. 38
31395054 2019
Incidence, aetiology, and serotype spectrum analysis of adult hand, foot, and mouth disease patients: A retrospective observational cohort study in northern Zhejiang, China. 38
31100417 2019
Increased effector γδ T cells with enhanced cytokine production are associated with inflammatory abnormalities in severe hand, foot, and mouth disease. 38
31100712 2019
Efficient Blocking of Enterovirus 71 Infection by Heparan Sulfate Analogues Acting as Decoy Receptors. 38
31307190 2019
Immune responses against enterovirus A71 infection: Implications for vaccine success. 38
31369184 2019
A novel method for performing antigenic vaccine matching for foot-and-mouth disease in absence of the homologous virus. 38
31296377 2019
Model of persistent foot-and-mouth disease virus infection in multilayered cells derived from bovine dorsal soft palate. 38
31419374 2019
Foot-and-Mouth Disease Virus: Immunobiology, Advances in Vaccines and Vaccination Strategies Addressing Vaccine Failures-An Indian Perspective. 38
31426368 2019
Development of a recombinant vaccine against Foot and Mouth Disease utilizing mutant attenuated Listeria ivanovii strain as a live vector. 38
31422118 2019
Reliable detection, sequencing, and transfection of foot-and-mouth disease virus RNA from badly preserved vesicular epithelium. 38
31423909 2019
Genetic Determinants of Virulence between Two Foot-and-Mouth Disease Virus Isolates Which Caused Outbreaks of Differing Severity. 38
31413173 2019
[Clinical effect of carvedilol in treatment of children with severe hand-foot-mouth disease caused by enterovirus 71 infection]. 38
31416505 2019
Evaluating the utility of national-scale data to estimate the local risk of foot-and-mouth disease in endemic regions. 38
31408585 2019
Hydrogen peroxide vapour is an effective replacement for Formaldehyde in a BSL4 Foot and mouth disease vaccine manufacturing facility. 38
31376169 2019
Nationwide groundwater monitoring around infectious-disease-caused livestock mortality burials in Korea: Superimposed influence of animal leachate on pre-existing anthropogenic pollution. 38
31150979 2019
Persistent infection and transmission of Senecavirus A from carrier sows to contact piglets. 38
31434730 2019
[Association of interleukin-10 gene polymorphism with enterovirus 71 infection in children]. 38
31416504 2019
Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory. 38
31405637 2019
Antiviral activity of brequinar against foot-and-mouth disease virus infection in vitro and in vivo. 38
31146110 2019
Major Phytoconstituents of Prunus cerasoides Responsible for Antimicrobial and Antibiofilm Potential Against Some Reference Strains of Pathogenic Bacteria and Clinical Isolates of MRSA. 38
30854606 2019
A conserved RNA structural motif for organizing topology within picornaviral internal ribosome entry sites. 38
31399592 2019
Basal Level p53 Suppresses Antiviral Immunity against Foot-and-Mouth Disease Virus. 38
31394868 2019
Antiviral activity of merimepodib against foot and mouth disease virus in vitro and in vivo. 38
31386979 2019
The Clinical and Epidemiological Study of Children with Hand, Foot, and Mouth Disease in Hunan, China from 2013 to 2017. 38
31406192 2019
Construction and characterization of an infectious cDNA clone of coxsackievirus A 10. 38
31387601 2019
Necrotising fasciitis complicating hand, foot and mouth disease. 38
31434667 2019
Case report: painful exanthems caused by enterovirus D68 in an adolescent. 38
31415349 2019
Identification of plasticity and interactions of a highly conserved motif within a picornavirus capsid precursor required for virus infectivity. 38
31409836 2019
Picornaviruses and RNA Metabolism: Local and Global Effects of Infection. 38
31413128 2019
The use of bacteriophage MS2 for the development and application of a virucide decontamination test method for porous and heavily soiled surfaces. 38
31379024 2019
Hederacolchiside C inhibits Enterovirus 71 propagation through activating innate immunity. 38
31401030 2019
Persistent Infection of African Buffalo (Syncerus caffer) with Foot-and-Mouth Disease Virus: Limited Viral Evolution and No Evidence of Antibody Neutralization Escape. 38
31092573 2019
Validation of a high performance liquid chromatography method for quantitation of foot-and-mouth disease virus antigen in vaccines and vaccine manufacturing. 38
31353259 2019

Variations for Mouth Disease

Expression for Mouth Disease

Search GEO for disease gene expression data for Mouth Disease.

Pathways for Mouth Disease

Pathways related to Mouth Disease according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
12.99 TLR7 TLR4 TLR3 STAT1 IL6 IL10
Show member pathways
Show member pathways
Show member pathways
12.57 STAT1 IL6 IL17F IL10 IFNG
Show member pathways
12.51 TLR4 STAT1 NOTCH1 IL6 IL17F IL10
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.25 TLR7 TLR4 TLR3 IL6
Show member pathways
Show member pathways
12.24 TLR4 STAT1 IL10 IFNG
Show member pathways
Show member pathways
19 12.02 TLR7 TLR4 TLR3 STAT1 IL6 IFNG
Show member pathways
12.01 TLR7 TLR4 TLR3 STAT1
21 11.98 NOTCH1 IL6 IL10 IFNG
22 11.96 STAT1 IL6 IL17F IL10
Show member pathways
24 11.92 VTN IL6 IFNG BECN1
25 11.91 TLR4 IL6 IFNG
26 11.88 TLR4 IL6 IL10 IFNG
Show member pathways
11.84 TLR4 IL6 IL17F
28 11.84 TLR4 IL6 IFNG
29 11.82 STAT1 IL6 IL10 IFNG IFNA1
Show member pathways
11.8 STAT1 IL6 CRP
31 11.78 TLR4 IL6 IFNG
32 11.77 STAT1 IL6 IFNG
33 11.77 VTN TLR7 TLR4 TLR3
34 11.75 VDR TLR4 STAT1 IL6 IL10 IFNG
35 11.73 TLR4 IL6 IL10
36 11.7 IL6 IL10 IFNG
38 11.68 TLR7 IL6 IL10 IFNG
39 11.52 VTN IL6 HMGB1
40 11.49 NOTCH1 IL10 IFNG
41 11.49 TLR4 IL6 IL10 IFNG
42 11.48 VDR IL6 IFNG
43 11.38 IL6 IL10 IFNG
44 11.36 TLR4 IL6 IL10
Show member pathways
11.34 TLR7 TLR4 TLR3 STAT1 IL6 IL17F
46 11.24 IL6 IL10 IFNG

GO Terms for Mouth Disease

Cellular components related to Mouth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 VTN NOTCH1 IL6 IL17F IL10 IFNG
2 receptor complex GO:0043235 9.46 VDR TLR7 TLR4 NOTCH1
3 endosome membrane GO:0010008 9.35 TLR7 TLR4 TLR3 SCARB2 BECN1
4 endolysosome membrane GO:0036020 9.32 TLR7 TLR3
5 extracellular space GO:0005615 9.32 VTN TLR3 IL6 IL17F IL10 IFNG

Biological processes related to Mouth Disease according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 VDR TLR4 TLR3 NOTCH1 IL6 IFNG
2 cellular response to interferon-gamma GO:0071346 9.88 TLR4 TLR3 STAT1
3 positive regulation of JNK cascade GO:0046330 9.86 TLR4 TLR3 HMGB1
4 humoral immune response GO:0006959 9.86 NOTCH1 IL6 IFNG IFNA1
5 positive regulation of inflammatory response GO:0050729 9.85 TLR7 TLR4 TLR3
6 cellular response to mechanical stimulus GO:0071260 9.85 TLR7 TLR4 TLR3
7 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.84 TLR7 TLR4 TLR3 HMGB1
8 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.83 TLR7 TLR4 TLR3
9 positive regulation of tumor necrosis factor production GO:0032760 9.81 TLR4 TLR3 HMGB1
10 positive regulation of autophagy GO:0010508 9.8 IFNG HMGB1 BECN1
11 toll-like receptor signaling pathway GO:0002224 9.8 TLR7 TLR4 TLR3 HMGB1
12 response to exogenous dsRNA GO:0043330 9.79 TLR3 IFNA1 DDX58
13 positive regulation of interleukin-8 production GO:0032757 9.78 TLR7 TLR4 TLR3 DDX58
14 negative regulation of interferon-gamma production GO:0032689 9.77 TLR4 IL10 HMGB1
15 inflammatory response GO:0006954 9.76 TLR7 TLR4 TLR3 IL6 IL17F IL10
16 positive regulation of interleukin-6 secretion GO:2000778 9.75 IL17F HMGB1 DDX58
17 positive regulation of interleukin-12 production GO:0032735 9.73 TLR4 TLR3 IFNG HMGB1
18 I-kappaB phosphorylation GO:0007252 9.72 TLR7 TLR4 TLR3
19 stress granule assembly GO:0034063 9.71 G3BP2 G3BP1
20 positive regulation of keratinocyte differentiation GO:0045618 9.71 VDR NOTCH1
21 interleukin-6-mediated signaling pathway GO:0070102 9.7 STAT1 IL6
22 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.7 TLR4 STAT1
23 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.69 STAT1 IFNG
24 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.69 TLR7 TLR3
25 inflammatory response to antigenic stimulus GO:0002437 9.69 NOTCH1 HMGB1
26 positive regulation of interferon-beta biosynthetic process GO:0045359 9.69 TLR7 TLR4 TLR3
27 negative regulation of interleukin-17 production GO:0032700 9.68 TLR4 IFNG
28 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.68 TLR4 TLR3
29 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.67 TLR7 TLR4
30 positive regulation of interferon-alpha secretion GO:1902741 9.67 HMGB1 DDX58
31 positive regulation of chemokine production GO:0032722 9.67 TLR7 TLR4 TLR3 IL6
32 negative regulation of lipid storage GO:0010888 9.66 IL6 CRP
33 response to glucocorticoid GO:0051384 9.66 IL6 IL10
34 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 TLR4 IL10
35 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.64 TLR4 TLR3
36 cytoplasmic sequestering of NF-kappaB GO:0007253 9.64 IL10 G3BP2
37 detection of virus GO:0009597 9.63 TLR3 DDX58
38 positive regulation of interferon-beta production GO:0032728 9.63 TLR4 TLR3 DDX58
39 positive regulation of interferon-alpha biosynthetic process GO:0045356 9.62 TLR7 TLR3
40 regulation of dendritic cell cytokine production GO:0002730 9.58 TLR4 TLR3
41 positive regulation of interferon-alpha production GO:0032727 9.43 TLR4 STAT1 DDX58
42 positive regulation of interleukin-6 production GO:0032755 9.43 TLR7 TLR4 TLR3 IL6 HMGB1 DDX58
43 positive regulation of wound healing GO:0090303 9.4 VTN
44 regulation of signaling receptor activity GO:0010469 9.27 HMGB1
45 defense response to virus GO:0051607 9.23 TLR7 TLR3 STAT1 IL6 IFNG IFNA1
46 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 VDR TLR4 TLR3 STAT1 NOTCH1 IL6
47 innate immune response GO:0045087 10.08 TLR7 TLR4 TLR3 HMGB1 DDX58 CRP
48 immune response GO:0006955 10.07 VTN TLR7 TLR4 NOTCH1 IL6 IL10
49 negative regulation of cell proliferation GO:0008285 10.05 VDR NOTCH1 IL6 IL10 BECN1
50 cytokine-mediated signaling pathway GO:0019221 10 STAT1 IL6 IL17F IL10 IFNA1

Molecular functions related to Mouth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.67 VDR TLR4 TLR3 NOTCH1
2 transmembrane signaling receptor activity GO:0004888 9.55 TLR7 TLR4 TLR3 SCARB2 NOTCH1
3 single-stranded RNA binding GO:0003727 9.26 TLR7 DDX58
4 double-stranded RNA binding GO:0003725 9.13 TLR7 TLR3 DDX58
5 cytokine activity GO:0005125 9.1 IL6 IL17F IL10 IFNG IFNA1 HMGB1
6 protein binding GO:0005515 10.25 VTN VDR TLR4 TLR3 STAT1 SCARB2

Sources for Mouth Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....